Drug Trial Radar · NCT05158387
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,172
Actual
Start
Feb 7, 2022
Primary completion
Jan 19, 2026
Study completion Mar 22, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TozorakimabDrug
Administered subcutaneously tozorakimab Dose 1 and placebo through Week 52.
TozorakimabDrug
Administered subcutaneously tozorakimab Dose 2 through Week 52.
PlaceboDrug
Placebo administered subcutaneously, equivalent volume to tozorakimab through week 52.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.Time frame: over 52 weeks
Locations
212 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
Sheffield, Alabama
Research Site
Lincoln, California
Research Site
Newport Beach, California
Research Site
Northridge, California
Research Site
Colorado Springs, Colorado
Research Site
Newark, Delaware
Research Site
Bay Pines, Florida
Research Site
Cape Coral, Florida
Research Site
Pensacola, Florida
Research Site
Tampa, Florida
Research Site
Winter Park, Florida
Research Site
Macon, Georgia
Research Site
Greenwood, Indiana
Research Site
Bowling Green, Kentucky
Research Site
White Marsh, Maryland
Research Site
North Dartmouth, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Farmington Hills, Michigan
Research Site
Grand Rapids, Michigan
Research Site
Buffalo, New York
Research Site
The Bronx, New York
Research Site
Toledo, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Tulsa, Oklahoma
Research Site
Philadelphia, Pennsylvania
Research Site
Rock Hill, South Carolina
Research Site
Amarillo, Texas
Research Site
Boerne, Texas
Research Site
Fort Worth, Texas
Research Site
McKinney, Texas
Research Site
Tomball, Texas
Research Site
Webster, Texas
Research Site
Williamsburg, Virginia
Research Site
Cudahy, Wisconsin
Research Site
Campbelltown, Australia
Research Site
Frankstown, Australia
Research Site
Macquarie University, Australia
Research Site
Melbourne, Australia
Research Site
Nedlands, Australia
Research Site
Southport, Australia
Showing 40 of 212 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.